Is Johnson & Johnson behind on manufacturing goals for its COVID-19 vaccine?

Wednesday, February 24, 2021
By Remaya Campbell

Required U.S. regulatory approval could come as soon as Feb. 27 for a single-dose COVID-19 vaccine developed by Johnson & Johnson, but manufacturing of the vaccine is running behind schedule.

The New York Times reported on Feb. 24 that the company will have four million does ready to ship at the end of February. Originally the company promised triple that volume by then. By the end of March the company will still be 17 million doses short of the original goals laid out last August, when the U.S. government ordered 100 million does of the vaccine. The company “insists” it will fulfill the total $1 billion order by the end of June, the Times said.

Federal regulators released analyses confirming that the new vaccine is safe, “with noticeably milder side effects than the Pfizer and Moderna vaccines, and without any reports of severe allergic reactions like anaphylaxis,” the Times added.

This Fact Brief is responsive to conversations such as this one.
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Lab. Over the course of these two years, Gigafact Lab writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Lab reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.